AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33921737 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness training protocol consisting of three weekly sessions lasting 90 min
Number of subjects: 40
Study 33921737 — intervention group
Group type: COMPARATOR
Intervention: Walking for 30-60 min three days a week without running or resistance training
Number of subjects: 40
Study 32413530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules
Number of subjects: 101
Study 32413530 — intervention group
Group type: COMPARATOR
Intervention: Beetroot-containing placebo capsules
Number of subjects: 101
Study 36353918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with extra-virgin olive oil
Number of subjects: 463
Study 36353918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with nuts
Number of subjects: 463
Study 36353918 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-reduced Mediterranean diet with physical activity
Number of subjects: 463
Study 36353918 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 463
Study 36353918 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum Mediterranean diet
Number of subjects: 463
Study 33990958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) of 60 mm Hg using norepinephrine (NE) infusion
Number of subjects: 0
Study 33990958 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure (MAP) of 90 mm Hg using norepinephrine (NE) infusion
Number of subjects: 0
Study 32830901 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa + donepezil (5 mg)
Number of subjects: 20
Study 32830901 — intervention group
Group type: COMPARATOR
Intervention: levodopa
Number of subjects: 20
Study 33893064 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block appliance (RCT)
Number of subjects: 63
Study 33893064 — intervention group
Group type: COMPARATOR
Intervention: Retrospectively selected cases (RSC) treated with Twin Block appliance
Number of subjects: 63
Study 32534763 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics, prebiotics, and psyllium product
Number of subjects: 10
Study 32534763 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 10
Study 36548296 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP goal of 65 to 85 mmHg (L group)
Number of subjects: 116
Study 36548296 — intervention group
Group type: COMPARATOR
Intervention: MAP goal of 86 to 100 mmHg (H group)
Number of subjects: 116
Study 33485960 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1189
Study 33485960 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1189
Study 32393614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 826
Study 32393614 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 826
Study 35063002 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine collaborative model (TCMCM) combined with usual adjuvant chemotherapy
Number of subjects: 260
Study 35063002 — intervention group
Group type: COMPARATOR
Intervention: Usual adjuvant chemotherapy
Number of subjects: 260
Study 32896933 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS and MBM regimen
Number of subjects: 19
Study 32896933 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS and MBM regimen
Number of subjects: 19
Study 35582947 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 6480
Study 35582947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6480
Study 33647220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence length (2 to 7 words)
Number of subjects: 62
Study 32335550 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT + EVT
Number of subjects: 9117
Study 32335550 — intervention group
Group type: COMPARATOR
Intervention: dEVT
Number of subjects: 9117
Study 35038562 — intervention group
Group type: EXPERIMENTAL
Intervention: Social stress (n = 40)
Number of subjects: 80
Study 35038562 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 40)
Number of subjects: 80
Study 35038562 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressed participants
Number of subjects: 80
Study 33712252 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PECS block
Number of subjects: 90
Study 33712252 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative PECS block
Number of subjects: 90
Study 33712252 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 32969289 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related internet use (Y/N)
Number of subjects: 425
Study 32969289 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related internet use
Number of subjects: 425
Study 34448033 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 5095
Study 35410405 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE + RFA + Apatinib
Number of subjects: 175
Study 35410405 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE + Apatinib
Number of subjects: 175
Study 35410405 — intervention group
Group type: COMPARATOR
Intervention: TACE Alone
Number of subjects: 175
Study 32199246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive load induced by the verb generation task
Number of subjects: 0
Study 32199246 — intervention group
Group type: COMPARATOR
Intervention: Control baseline condition (no verb generation task)
Number of subjects: 0
Study 36006698 — intervention group
Group type: EXPERIMENTAL
Intervention: MoVo‐LISA intervention
Number of subjects: 202
Study 36006698 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment‐as‐usual)
Number of subjects: 202
Study 34580282 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (20 min, 2 mA) before every Lokomat session (30 min, 3 times a week for 12 weeks or 5 times a week for 6 weeks)
Number of subjects: 43
Study 34580282 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (20 min, 2 mA) before every Lokomat session (30 min, 3 times a week for 12 weeks or 5 times a week for 6 weeks)
Number of subjects: 43
Study 34580282 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 43
Study 34580282 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 43
Study 33308548 — intervention group
Group type: EXPERIMENTAL
Intervention: Service-learning experience
Number of subjects: 35
Study 33308548 — intervention group
Group type: EXPERIMENTAL
Intervention: Research training
Number of subjects: 35
Study 34062937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat β-Glucan (1 g OBG, n = 104)
Number of subjects: 207
Study 34062937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat β-Glucan (1 g OBG)
Number of subjects: 207
Study 34062937 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 103)
Number of subjects: 207
Study 32077300 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness committee implementation index (WC index)
Number of subjects: 23
Study 32077300 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness committee (WC)
Number of subjects: 23
Study 35560850 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% kcal carbohydrate diet
Number of subjects: 12
Study 35560850 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% kcal carbohydrate diet
Number of subjects: 12
Study 35560850 — intervention group
Group type: EXPERIMENTAL
Intervention: All dietary treatments (10%, 15%, 20%, 25%, 30% kcal carbohydrate)
Number of subjects: 12
Study 35560850 — intervention group
Group type: EXPERIMENTAL
Intervention: All dietary treatments
Number of subjects: 12
Study 34180414 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIÉ intervention (twice weekly classes for 12 weeks)
Number of subjects: 18
Study 32298656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 100
Study 32298656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35733098 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional speech therapy + functional electrotherapy
Number of subjects: 33
Study 35733098 — intervention group
Group type: COMPARATOR
Intervention: Conventional speech therapy
Number of subjects: 33
Study 32013412 — intervention group
Group type: EXPERIMENTAL
Intervention: MnIV4O4 complex
Number of subjects: 0
Study 32013412 — intervention group
Group type: COMPARATOR
Intervention: MnIIIMnIV3O4 cuboidal complex
Number of subjects: 0
Study 35615728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin treatment
Number of subjects: 40
Study 35615728 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 36341216 — intervention group
Group type: COMPARATOR
Intervention: 25, 75, 150, 300, 450, or 600 mg tafolecimab subcutaneously, 75 or 450 mg intravenously
Number of subjects: 118
Study 36341216 — intervention group
Group type: COMPARATOR
Intervention: 75 or 140 mg tafolecimab every 2 weeks, 300 or 420 mg every 4 weeks, or 450 or 600 mg every 6 weeks subcutaneously
Number of subjects: 118
Study 36341216 — intervention group
Group type: COMPARATOR
Intervention: Single dose of tafolecimab
Number of subjects: 118
Study 35954581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dosing intervals
Number of subjects: 193
Study 35954581 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible dosing intervals
Number of subjects: 193
Study 35954581 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 193
Study 32348815 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational approach (knowledge group)
Number of subjects: 448
Study 32348815 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect-based approach (affect group)
Number of subjects: 448
Study 32348815 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 448
Study 33039478 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy (AIT) with allergoids to birch and/or grass
Number of subjects: 0
Study 33039478 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 0
Study 32133662 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair of medial condylar fracture
Number of subjects: 43
Study 33682648 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation with sertraline (50 mg/day)
Number of subjects: 1549
Study 33682648 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation with sertraline (100 mg/day)
Number of subjects: 1549
Study 33682648 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized treatment (individualized treatment rule)
Number of subjects: 1549
Study 33682648 — intervention group
Group type: COMPARATOR
Intervention: Switching to mirtazapine
Number of subjects: 1549
Study 33682648 — intervention group
Group type: COMPARATOR
Intervention: Combining mirtazapine with sertraline
Number of subjects: 1549
Study 34998427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluralaner (oral administration at the approved dose on day 0)
Number of subjects: 12
Study 34998427 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated)
Number of subjects: 12
Study 33956987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventral posterior medial (VPM) stimulation
Number of subjects: 1
Study 33956987 — intervention group
Group type: EXPERIMENTAL
Intervention: Centromedian (CM) stimulation
Number of subjects: 1
Study 33956987 — intervention group
Group type: EXPERIMENTAL
Intervention: VPM-DBS in combination with lateral CM stimulation
Number of subjects: 1
Study 35419985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuttlebone toothpaste (Dr. D‐Tart)
Number of subjects: 81
Study 35419985 — intervention group
Group type: COMPARATOR
Intervention: Crest toothpaste (control)
Number of subjects: 81
Study 34289755 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg at steady-state with levothyroxine (600 μg single-dose)
Number of subjects: 45
Study 34289755 — intervention group
Group type: COMPARATOR
Intervention: SNAC 300 mg with levothyroxine (600 μg single-dose)
Number of subjects: 45
Study 34289755 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide 14 mg at steady-state with five placebo tablets
Number of subjects: 45
Study 34289755 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide 14 mg at steady-state alone
Number of subjects: 45
Study 32723352 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate mucoadhesive tablet
Number of subjects: 46
Study 32723352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 35099205 — intervention group
Group type: EXPERIMENTAL
Intervention: eBridge (personalized feedback with option of online counseling)
Number of subjects: 3363
Study 35099205 — intervention group
Group type: COMPARATOR
Intervention: Control (personalized feedback)
Number of subjects: 3363
Study 33475701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg
Number of subjects: 613
Study 33475701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab 2800 mg
Number of subjects: 613
Study 33475701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab 7000 mg
Number of subjects: 613
Study 33475701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab and Etesevimab (2800 mg each)
Number of subjects: 613
Study 33475701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study 33886909 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone monitoring for symptoms, quality of life, distress, admissions to the emergency center, and satisfaction
Number of subjects: 81
Study 33886909 — intervention group
Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 81
Study 35597385 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-Expandable Valve (BEV) SAPIEN (3/ULTRA, Edwards Lifesciences)
Number of subjects: 102
Study 35597385 — intervention group
Group type: COMPARATOR
Intervention: Self-Expanding Valve (SEV) Evolut (R/PRO/PRO+, Medtronic)
Number of subjects: 102
Study 35597385 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive valve hemodynamic evaluation (both groups)
Number of subjects: 102
Study 33235041 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized pain management education
Number of subjects: 267
Study 33235041 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 267
Study 32175948 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath video laryngoscope
Number of subjects: 130
Study 32175948 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscopy
Number of subjects: 130
Study 32968915 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐TEP
Number of subjects: 92
Study 32968915 — intervention group
Group type: COMPARATOR
Intervention: IPOM Plus
Number of subjects: 92
Study 32977831 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 105
Study 32977831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 33830234 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 50
Study 33830234 — intervention group
Group type: COMPARATOR
Intervention: Sham needling
Number of subjects: 50
Study 32164563 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-c increase
Number of subjects: 573
Study 32164563 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Cholesterol (TC) increase at 20 weeks gestation
Number of subjects: 573
Study 32164563 — intervention group
Group type: COMPARATOR
Intervention: Low HDL-c at enrolment
Number of subjects: 573
Study 32164563 — intervention group
Group type: COMPARATOR
Intervention: Low HDL-c at 20 weeks gestation
Number of subjects: 573
Study 32164563 — intervention group
Group type: COMPARATOR
Intervention: High LDL-c at 30 weeks gestation
Number of subjects: 573
Study 32164563 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Cholesterol (TC) increase at 30 weeks gestation
Number of subjects: 573
Study 32164563 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-c increase at 30 weeks gestation
Number of subjects: 573
Study 33836708 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually targeted human milk fortification with protein and fat modulars based on daily point‐of‐care milk analysis.
Number of subjects: 130
Study 33836708 — intervention group
Group type: COMPARATOR
Intervention: Standard fortification (control group).
Number of subjects: 130
Study 33221776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block
Number of subjects: 74
Study 33221776 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration (WI)
Number of subjects: 74
Study 35380713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 500 mg/m2, bevacizumab 5 mg/kg, and irinotecan 180 mg/m2 (CBI)
Number of subjects: 36
Study 35380713 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab and irinotecan with placebo (CI)
Number of subjects: 36
Study 32713051 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of sugar-sweetened beverages (SSBs) from sale in hospitals
Number of subjects: 2394
Study 32713051 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for SSB removal among staff and visitors
Number of subjects: 2394
Study 32713051 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of health improvement due to SSB removal
Number of subjects: 2394
Study 32713051 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of SSB removal among staff vs visitors
Number of subjects: 2394
Study 32772304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists providing clinical pharmacy services
Number of subjects: 119
Study 32772304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists reviewing medication orders
Number of subjects: 119
Study 32772304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists monitoring patients' response to therapy and adverse drug effects
Number of subjects: 119
Study 32772304 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with pharmacists in developing treatment plans
Number of subjects: 119
Study 32772304 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving doctor-pharmacist collaborations through trust and dialogue
Number of subjects: 119
Study 32772304 — intervention group
Group type: COMPARATOR
Intervention: Demographic characteristics related to doubt in pharmacist clinical competence
Number of subjects: 119
Study 34825307 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (5 years treatment)
Number of subjects: 1735
Study 34825307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CCTG MA.17R trial)
Number of subjects: 1735
Study 32471770 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education and SMS reminders for six months
Number of subjects: 101
Study 32471770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 101
Study 32693615 — intervention group
Group type: EXPERIMENTAL
Intervention: N-butyl-cyanoacrylate + Metacryloxysulfolane
Number of subjects: 142
Study 32693615 — intervention group
Group type: COMPARATOR
Intervention: Suture Alone
Number of subjects: 142
Study 33234638 — intervention group
Group type: EXPERIMENTAL
Intervention: Choosing Health digital intervention
Number of subjects: 285
Study 33234638 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-tailored weight loss advice via e-book and generic emails)
Number of subjects: 285
Study 34187067 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic arm-assisted TKA (RA-TKA)
Number of subjects: 340
Study 34187067 — intervention group
Group type: COMPARATOR
Intervention: Manual TKA
Number of subjects: 340
Study 34187067 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RA-TKA and Manual TKA
Number of subjects: 340
Study 34798826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led, deprescribing-focused medication review, followed by an individualised treatment modification plan.
Number of subjects: 62
Study 34798826 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 62
Study 32721212 — intervention group
Group type: EXPERIMENTAL
Intervention: 174 Hz unweighted tuning fork (TF) used by practitioners to comb the same four sites per subject
Number of subjects: 10
Study 32721212 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis using a Monte Carlo approach
Number of subjects: 10
Study 35974369 — intervention group
Group type: EXPERIMENTAL
Intervention: Exp I: active and passive activity training (APAT) + NMES treatment on the gastrocnemius and tibialis anterior muscle
Number of subjects: 0
Study 35974369 — intervention group
Group type: EXPERIMENTAL
Intervention: Exp II: APAT + NMES treatment on gastrocnemius alone
Number of subjects: 0
Study 35974369 — intervention group
Group type: COMPARATOR
Intervention: Ctl: APAT alone
Number of subjects: 0
Study 33958128 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional support to reach energy, protein, and micronutrient goals
Number of subjects: 645
Study 33958128 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital food
Number of subjects: 645
Study 33958128 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 645
Study 32804970 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (specific regimens not detailed)
Number of subjects: 273
Study 32804970 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTIs
Number of subjects: 273
Study 32804970 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTIs
Number of subjects: 273
Study 32804970 — intervention group
Group type: EXPERIMENTAL
Intervention: PIs
Number of subjects: 273
Study 32804970 — intervention group
Group type: EXPERIMENTAL
Intervention: M184V mutation
Number of subjects: 273
Study 32804970 — intervention group
Group type: EXPERIMENTAL
Intervention: K65R mutation
Number of subjects: 273
Study 32804970 — intervention group
Group type: EXPERIMENTAL
Intervention: TAMs
Number of subjects: 273
Study 32804970 — intervention group
Group type: EXPERIMENTAL
Intervention: K103N mutation
Number of subjects: 273
Study 32804970 — intervention group
Group type: EXPERIMENTAL
Intervention: Other NNRTI mutations
Number of subjects: 273
Study 36137090 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (interactive computerised presentations)
Number of subjects: 10
Study 36137090 — intervention group
Group type: COMPARATOR
Intervention: Active control procedure
Number of subjects: 10